Loading clinical trials...

Therapy Optimization in Multiple Sclerosis (MS) | Clinical Trials | Clareo Health

COMPLETED

Therapy Optimization in Multiple Sclerosis (MS)

TOP MS is a Study of Multiple Sclerosis Disease Management in Collaboration With Specialty Pharmacies

NCT00819000•Teva Neuroscience, Inc.

Summary

The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female, 18 years of age or older, with a diagnosis of MS.
•Being treated with Glatiramer Acetate (GA) or (IFN)-β
•Receiving therapy from a participating Specialty Pharmacy

Exclusion Criteria

•Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study
•Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)
•Unlikely to be able to participate for the full two years of the study

Locations (3)

Teva Investigational Site

Swartz Creek, Michigan, United States

Teva Investigational Site

Columbus, Ohio, United States

Teva Investigational Site

Carnegie, Pennsylvania, United States

Key Dates

Start Date

December 1, 2008

Primary Completion Date

December 1, 2012

Completion Date

January 1, 2013

Last Updated

January 29, 2013

Enrollment

2,878

ACTUAL participants

Conditions

Multiple Sclerosis

Interventions

Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b

DRUG

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGNA

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Therapy Optimization in Multiple Sclerosis (MS)

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Intermittent Hypoxia in Persons With Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis